ILEVRO
Peaknepafenac
NDAOPHTHALMICSUSPENSION/DROPS
Approved
Oct 2012
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
16
Data completeness
6/8 — Strong
ILEVRO (nepafenac) is cyclooxygenase inhibitors [moa]. First approved in 2012.
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ILEVRO (nepafenac) is a topical ophthalmic nonsteroidal anti-inflammatory drug (NSAID) suspension administered as eye drops. It works by inhibiting cyclooxygenase enzymes to reduce inflammation and pain in the eye. The drug is indicated for ophthalmic inflammatory conditions and is in its peak commercial lifecycle stage.
$20MPart D
PeakStable
5.7 years to LOEThe product is at peak lifecycle with modest Part D spending of $20M and approximately 50k annual claims, indicating a stable but limited-scale market suitable for focused commercial teams.
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (16)
Tolerability and Toxicity of Topically Applied Nepafenac 0.3% vs Ketorolac 0.5%
Started Apr 2016
200 enrolled
Cataract
Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial
Started Oct 2013
57 enrolled
Treatment of Ocular Inflammation Associated With Cataract Surgery
Nepafenac Once Daily for Macular Edema - Study 2
Started Jun 2013
819 enrolled
Non-Proliferative Diabetic RetinopathyCataract
Nepafenac Once Daily for Macular Edema - Study 1
Started Jun 2013
881 enrolled
Non-Proliferative Diabetic RetinopathyCataract
Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery
Started Apr 2013
50 enrolled
CataractRetinal EdemaInflammation
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.